Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors

Stergios J. Moschos, Ryan J. Sullivan, Wen Jen Hwu, Ramesh K. Ramanathan, Alex A. Adjei, Peter C. Fong, Ronnie Shapira-Frommer, Hussein A. Tawbi, Joseph Rubino, Thomas S. Rush, Da Zhang, Nathan R. Miselis, Ahmed A. Samatar, Patrick Chun, Eric H. Rubin, James Schiller, Brian J. Long, Priya Dayananth, Donna Carr, Paul KirschmeierW. Robert Bishop, Yongqi Deng, Alan Cooper, Gerald W. Shipps, Blanca Homet Moreno, Lidia Robert, Antoni Ribas, Keith T. Flaherty

Research output: Contribution to journalArticlepeer-review

45 Scopus citations

Fingerprint Dive into the research topics of 'Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences